Heat shock protein 90 is a promising target for effective growth inhibition of gastrointestinal neuroendocrine tumors

International Journal of Oncology

Volumn 40, Issue 5, 2012, Pages 1659-1667

  Gloesenkamp, Christoph ^a   Nitzsche, Bianca ^a,b   Lim, Alice R ^c   Normant, Emmanuel ^c   Vosburgh, Evan ^d   Schrader, Mark ^e   Ocker, Matthias ^f   Scherübl, Hans ^g   Höpfner, Michael ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b Berlin Institute for Urologic Research   (Germany)

^c Infinity Pharmaceuticals Inc   (United States)

^d 1 Stamford Forum   (United States)

^e UNIVERSITY OF ULM   (Germany)

^f PHILIPPS UNIVERSITY MARBURG   (Germany)

^g VIVANTES KLINIKUM AM URBAN   (Germany)

Author keywords

AKT mTOR; Carcinoid; Chick chorioallantoic membrane assay; Gastroenteropancreatic neuro endocrine tumors; Heat shock protein 90; IGF 1R

Indexed keywords

DOXORUBICIN; EVEROLIMUS; HEAT SHOCK PROTEIN 90; MAMMALIAN TARGET OF RAPAMYCIN; NVP AEW 541; PROTEIN KINASE B; PROTEIN TYROSINE KINASE; RAPAMYCIN; RETASPIMYCIN; SOMATOMEDIN C RECEPTOR; TRICIRIBINE;

ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CANCER INHIBITION; CELL ASSAY; CELL CYCLE ARREST; CHORIOALLANTOIS; DOSE RESPONSE; DOWN REGULATION; DRUG MECHANISM; DRUG TARGETING; ENZYME INHIBITION; FLUORESCENCE ACTIVATED CELL SORTING; GASTROENTEROPANCREATIC NEUROENDOCRINE TUMOR; GASTROINTESTINAL TUMOR; GENE EXPRESSION PROFILING; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VIVO STUDY; INSULINOMA; NEUROENDOCRINE TUMOR; PANCREAS CANCER; PRIORITY JOURNAL;

ANIMALS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; BENZOQUINONES; CELL CYCLE CHECKPOINTS; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; CHICK EMBRYO; CHORIOALLANTOIC MEMBRANE; DOSE-RESPONSE RELATIONSHIP, DRUG; FLOW CYTOMETRY; GASTROINTESTINAL NEOPLASMS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HSP90 HEAT-SHOCK PROTEINS; HUMANS; LACTAMS, MACROCYCLIC; NEUROENDOCRINE TUMORS; PHOSPHATIDYLINOSITOL 3-KINASE; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTOR, IGF TYPE 1; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES;

EID: 84860315005     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2012.1328     Document Type: Article

References (45)

1. Klöppel G, Perren A and Heitz PU: The gastroenteropancreatic neuroendocrine cell system and its tumors: the WHO classification. Ann NY Acad Sci 1014: 13-27, 2004. (Pubitemid 38594787)
2. Rindi G, Klöppel G, Alhman H, et al: TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system. Virchows Arch 449: 395-401, 2006. (Pubitemid 44451313)
3. Modlin IM, Lye KD and Kidd M: A 5-decade analysis of 13,715 carcinoid tumors. Cancer 97: 934-959, 2003. (Pubitemid 36173145)
4. Norton J: Surgery for primary pancreatic neuroendocrine tumors. J Gastrointest Surg 10: 327-331, 2006.
5. Öberg K and Jelic S: On behalf of the ESMO Guidelines Working Group. Neuroendocrine gastroenteropancreatic tumors: ESMO Clinical Recommendation for diagnosis, treatment and follow-up. Ann Oncol 20 (Suppl. 4): iv150-iv153, 2009.
6. Neckers L: Heat shock protein 90: the cancer chaperone. J Biosci 32: 517-530, 2007.
7. Pitt SC, Ruth D, Kunnimalaiyaan M and Chen H: AKT and PTEN expression in human gastrointestinal carcinoid tumors. Am J Transl Res 1: 291-299, 2009.
8. Gilbert JA, Adhikari LJ, Lloyd RV, et al: Molecular markers for novel therapies in neuroendocrine (carcinoid) tumors. Endocr Relat Cancer 17: 623-636, 2010.
9. McDonough H and Patterson C: CHIP: a link between the chaperone and proteasome systems. Cell Stress Chaperones 8: 303-308, 2003. (Pubitemid 38222876)
10. Lang SA, Moser C, Gaumann A, et al: Targeting heat shock protein 90 in pancreatic cancer impairs insulin-like growth factor-I receptor signaling, disrupts an interleukin-6/signal-transducer and activator of transcription 3/hypoxia-inducible factor-1α autocrine loop, and reduces orthotopic tumor growth. Clin Cancer Res 13: 6459-6468, 2007. (Pubitemid 350075036)
11. Sydor JR, Normant E, Pien CS, et al: Development of 17-allyl-amino-17- demethoxygeldanamycin hydroquinone hydrochloride (IPI-504), an anti-cancer agent directed against Hsp90. Proc Natl Acad Sci USA 103: 17408-17413, 2006. (Pubitemid 44788982)
12. Evers BM, Townsend CM, Upp JR, et al: Establishment and characterization of a human carcinoid in nude mice and effect of various agents on tumor growth. Gastroenterology 101: 303-311, 1991.
13. Baroni MG, Cavallo MG, Mark M, et al: Beta-cell gene expression and functional characterisation of the human insulinoma cell line CM. J Endocrinol 161: 59-68, 1999. (Pubitemid 29170192)
14. Gillies RJ, Didier N and Denton M: Determination of cell number in monolayer cultures. Anal Biochem 159: 109-113, 1986. (Pubitemid 17228232)
15. Höpfner M, Baradari V, Huether A, Schöfl C and Scherübl H: The insulin-like growth factor receptor 1 is a promising target for novel treatment approaches in neuroendocrine gastrointestinal tumours. Endocr Relat Cancer 13: 135-149, 2006.
16. Gebäck T, Schulz MMP, Koumoutsakos P and Detmar M: TScratch: a novel and simple software tool for automated analysis of monolayer wound healing assays. Biotechniques 46: 265-274, 2009.
17. Fried J, Perez A and Clarkson B: Flow cytofluorometric analysis of cell cycle distributions using propidium iodide. Properties of the method and mathematical analysis of the data. J Cell Biol 71: 172-181, 1976.
18. Nitzsche B, Glösenkamp C, Schrader M, et al: Novel compounds with antiangiogenic and antiproliferative potency for growth control of testicular germ cell tumours. Br J Cancer 103: 18-28, 2010.
19. Wan X, Harkavy B, Shen N, Grohar P and Helman LJ: Rapamycin induces feedback activation of Akt signaling through an IGF-1R-dependent mechanism. Oncogene 26: 1932-1940, 2007. (Pubitemid 46474636)
20. Herbig U, Jobling WA, Chen BPC, Chen DJ and Sedivy JM: Telomere shortening triggers senescence of human cells through a pathway involving ATM, p53, and p21(CIP1), but not p16(INK4a). Mol Cell 14: 501-513, 2004. (Pubitemid 38648803)
21. Somasundaram K, Zhang H, Zeng Y, et al: Arrest of the cell cycle by the tumour-suppressor BRCA1 requires the CDK-inhibitor p21WAF1/CIPl. Nature 389: 187-190, 1997. (Pubitemid 27400601)
22. Johnson DG and Walker CL: Cyclins and cell cycle checkpoints. Annu Rev Pharmacol Toxicol 39: 295-312, 1999. (Pubitemid 29222561)
23. Altieri DC: Survivin, versatile modulation of cell division and apoptosis in cancer. Oncogene 22: 8581-8589, 2003.
24. Panzuto F, Di Fonzo M, Iannicelli E, et al: Long-term clinical outcome of somatostatin analogues for treatment of progressive, metastatic, well-differentiated entero-pancreatic endocrine carcinoma. Ann Oncol 17: 461-466, 2006. (Pubitemid 43329584)
25. Kouvaraki MA, Ajani JA, Hoff P, et al: Fluorouracil, doxorubicin, and streptozocin in the treatment of patients with locally advanced and metastatic pancreatic endocrine carcinomas. J Clin Oncol 22: 4762-4771, 2004.
26. Mahalingam D, Swords R, Carew JS, et al: Targeting HSP90 for cancer therapy. Br J Cancer 100: 1523-1529, 2009.
27. Ciocca DR and Calderwood SK: Heat shock proteins in cancer: diagnostic, prognostic, predictive, and treatment implications. Cell Stress Chaperones 10: 86-103, 2005. (Pubitemid 40942470)
28. Höpfner M, Schuppan D and Scherübl H: Treatment of gastrointestinal neuroendocrine tumors with inhibitors of growth factor receptors and their signaling pathways: Recent advances and future perspectives. World J Gastroenterol 14: 2461-2473, 2008.
29. Trepel J, Mollapour M, Giaccone G and Neckers L: Targeting the dynamic HSP90 complex in cancer. Nat Rev Cancer 10: 537-549, 2010.
30. Höpfner M, Sutter AP, Gerst B, Zeitz M and Scherübl H: A novel approach in the treatment of neuroendocrine gastrointestinal tumours. Targeting the epidermal growth factor receptor by gefitinib (ZD1839). Br J Cancer 89: 1766-1775, 2003.
31. Von Wichert G, Haeussler U, Greten FR, et al: Regulation of cyclin D1 expression by autocrine IGF-I in human BON neuroendocrine tumour cells. Oncogene 24: 1284-1289, 2005. (Pubitemid 40313930)
32. Basso AD, Solit DB, Chiosis G, et al: Akt forms an intracellular complex with heat shock protein 90 (Hsp90) and Cdc37 and is destabilized by inhibitors of Hsp90 function. J Biol Chem 277: 39858-39866, 2002. (Pubitemid 35190971)
33. Kim T, Jang C, Kim HD, et al: Interaction of Hsp90 with ribosomal proteins protects from ubiquitination and proteasome-dependent degradation. Mol Biol Cell 17: 824-833, 2006. (Pubitemid 43191116)
34. Yao JC, Lombard-Bohas C, Baudin E, et al: Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a phase II trial. J Clin Oncol 28: 69-76, 2010.
35. Sarbassov DD, Guertin DA, Ali SM and Sabatini DM: Phospho-rylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 307: 1098-1101, 2005. (Pubitemid 40262113)
36. O'Reilly KE, Rojo F, She Q, et al: mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res 66: 1500-1508, 2003. (Pubitemid 43259931)
37. Liu T, Koul D, LaFortune T, et al: NVP-BEZ235, a novel dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor, elicits multifaceted antitumor activities in human gliomas. Mol Cancer Ther 8: 2204-2210, 2009.
38. Zou Z, Zhang X, Wang F, et al: A novel dual PI3Kalpha/mTOR inhibitor PI-103 with high antitumor activity in non-small cell lung cancer cells. Int J Mol Med 24: 97-101, 2009.
39. Sidera K and Patsavoudi E: Extracellular HSP90: conquering the cell surface. Cell Cycle 7: 1564-1568, 2008. (Pubitemid 351881322)
40. Stellas D, El Hamidieh A and Patsavoudi E: Monoclonal antibody 4C5 prevents activation of MMP2 and MMP9 by disrupting their interaction with extracellular HSP90 and inhibits formation of metastatic breast cancer cell deposits. BMC Cell Biol 11: 51, 2010.
41. Sun J and Liao JK: Induction of angiogenesis by heat shock protein 90 mediated by protein kinase Akt and endothelial nitric oxide synthase. Arterioscler Thromb Vasc Biol 24: 2238-2244, 2004. (Pubitemid 39658023)
42. Richardson PG, Mitsiades CS, Laubach JP, et al: Inhibition of heat shock protein 90 (HSP90) as a therapeutic strategy for the treatment of myeloma and other cancers. Br J Haematol 252: 367-379, 2011.
43. Gloesenkamp C, Nitzsche B, Ocker M, et al: AKT inhibition by triciribine alone or as combination therapy for growth control of gastroenteropancreatic neuroendocrine tumors. Int J Oncol 40: 876-888, 2012.
44. Yao JC, Shah MH, Ito T, et al: RAD001 in advanced neuroendocrine tumors, Third Trial (RADIANT-3) Study Group. Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med 364: 514-523, 2011.
45. Pries AR, Höpfner M, le Noble F, et al: The shunt problem: control of functional shunting in normal and tumour vasculature. Nat Rev Cancer 10: 587-593, 2010.